Filipe Gonçalves: Are DOACs Truly Pharmacokinetically Predictable or Simply Pharmacodynamically Forgiving?
Filipe Gonçalves, Docente at NOVA Medical School, shared a post on LinkedIn about a recent article by Joseph R. Shaw and Jack Ansell, published in Journal of Thrombosis and Haemostasis (JTH), adding:
”Are DOACs truly pharmacokinetically predictable or simply pharmacodynamically forgiving?
This article challenges a central assumption behind fixed-dose DOAC therapy.
Drug concentrations may vary considerably, while clinical effectiveness may persist because the pharmacodynamic response remains acceptable across a relatively broad exposure range.
It also highlights an important distinction between measuring drug concentration and measuring anticoagulant effect.
It also reminds us that commonly used thresholds such as 30 or 50 ng/mL are pragmatic decision cut-offs, not biologically validated safety boundaries.
A relevant perspective for pharmacology, laboratory medicine and urgent clinical decision-making.”
Title: A light in the dark—reframing direct oral anticoagulant pharmacokinetics and pharmacodynamics for near-patient decision-making
Authors: Joseph R. Shaw, Jack Ansell
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 29, 2026, 03:53Nahrwan Masaoodi: Iron Deficiency Can Exist Without Anemia
-
Sep 29, 2026, 03:38Muhammad Yousaf: Iron Deficiency Beyond Diet
-
Sep 29, 2026, 03:21Parvez Ahmed Chowdhury: Synthesizing Aspirin in the Organic Chemistry Lab
-
Sep 29, 2026, 03:12Ahmed Hamandi: Building the Future of Hematopoietic Transplantation in Iraq
-
Sep 29, 2026, 03:09M V Chandrakanth: Aspirin in CRC – Old Drug, New Precision Oncology?
-
Sep 29, 2026, 03:07Caroline Pothet: Advancing Treatment Development in Sickle Cell Disease and Thalassaemia
-
Sep 29, 2026, 02:53Astha Jain: Thalassemia Care Through a Public Health Lens
-
Sep 29, 2026, 02:50Emma Groarke: Starting a New Career Path in Homeland
-
Sep 28, 2026, 19:14Aditya Sharma: An Outstanding Start to the Final Day of VSS 2026!